Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
development of therapeutics for cancer and other diseases
|
| gptkbp:formerSubsidiaryOf |
gptkb:Sigma-Tau_Pharmaceuticals
|
| gptkbp:founded |
1981
|
| gptkbp:headquartersLocation |
gptkb:Bridgewater,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Enzon Pharmaceuticals, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
gptkb:Adagen
gptkb:PEG-Intron |
| gptkbp:status |
gptkb:public_company
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:ENZN
|
| gptkbp:technology |
gptkb:PEGylation
|
| gptkbp:tradedOn |
gptkb:ENZN
|
| gptkbp:website |
http://www.enzon.com/
|
| gptkbp:bfsParent |
gptkb:Enzon,_Inc.
|
| gptkbp:bfsLayer |
8
|